Diphenylpyraline

Diphenylpyraline
Clinical data
Other names	4-(diphenylmethoxy)-1-methyl-piperidine
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, Topical
ATC code	R06AA07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	24–40 hours
Identifiers
	IUPAC name 4-benzhydryloxy-1-methyl-piperidine;
CAS Number	147-20-6 ;
PubChem CID	3103;
IUPHAR/BPS	7165;
DrugBank	DB01146 ;
ChemSpider	2992 ;
UNII	33361OE3AV;
KEGG	D07862 ;
ChEBI	CHEBI:59788 ;
ChEMBL	ChEMBL1492 ;
CompTox Dashboard (EPA)	DTXSID3022952 ;
ECHA InfoCard	100.005.170
Chemical and physical data
Formula	C19H23NO
Molar mass	281.399 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(C(c1ccccc1)c2ccccc2)C3CCN(C)CC3;
	InChI InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 ; Key:OWQUZNMMYNAXSL-UHFFFAOYSA-N ;
	(verify)

Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenyl piperidine class.^[2]^[3]^[4] It is marketed in Europe for the treatment of allergies.^[2]^[3]^[5] DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents.^[6] It has been shown to be useful in the treatment of Parkinsonism.^[7]

Synthesis

Diphenylpyraline synthesis via coupling of 4-hydroxy-1-methylpiperidine with benzhydrylbromide^[8]^[9]

References

^ Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID 4156058. S2CID 38955052.
^ ^a ^b Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
^ ^a ^b Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. doi:10.1177/030006057700500106. PMID 14039. S2CID 19330175.
^ Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi:10.1254/jjp.43.277. PMID 2884340.
^ Hruby VJ, Vardanyan R, Vardanyan R (2006). "Antihistamine Drugs". Synthesis of Essential Drugs. Amsterdam: Elsevier. ISBN 0-444-52166-6.
^ Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID 15627433.
^ Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID 11137513. S2CID 35946097.
^ US 2479843, Knox LH, Kapp R, "1-Alkylpiperidyl-4-benzhydryl ethers, acid salts thereof and their preparation", issued 23 August 1949, assigned to Nopco Chemical Company.
^ DE 934890, Schuler WA, "Verfahren zur Herstellung von basischen Benzhydryläthern [Process for the production of basic benzhydrylethers]", issued 10 November 1955, assigned to Chemische Fabrik Promonta LLC.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[pmid4156058-1] Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID 4156058. S2CID 38955052.

[isbn3-88763-075-0-2] Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.

[pmid14039-3] Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. doi:10.1177/030006057700500106. PMID 14039. S2CID 19330175.

[pmid2884340-4] Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi:10.1254/jjp.43.277. PMID 2884340.

[isbn0-444-52166-6-5] Hruby VJ, Vardanyan R, Vardanyan R (2006). "Antihistamine Drugs". Synthesis of Essential Drugs. Amsterdam: Elsevier. ISBN 0-444-52166-6.

[pmid15627433-6] Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID 15627433.

[pmid11137513-7] Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID 11137513. S2CID 35946097.

[8] US 2479843, Knox LH, Kapp R, "1-Alkylpiperidyl-4-benzhydryl ethers, acid salts thereof and their preparation", issued 23 August 1949, assigned to Nopco Chemical Company.

[9] DE 934890, Schuler WA, "Verfahren zur Herstellung von basischen Benzhydryläthern [Process for the production of basic benzhydrylethers]", issued 10 November 1955, assigned to Chemische Fabrik Promonta LLC.

[2]

[3]

[4]

[5]

[6]

[7]

[1]

[8]

[9]

Diphenylpyraline

Synthesis

References

zproxy.org